Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn

Company News Summary

Imugene Reports Negative Cash Flow of $9.2m for the March 2022 Quarter

06 Jun 2022  |  06:46:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: Quarterly Activities/Appendix 4C Cash Flow Report

Imugene reported negative cash flow of $9.2m for quarter ended 31 March 2022. Operating cash flow for the period was $(10.84m). Investing cash flow was nil. Financing cash flow was $1.64m. Cash in hand at the end of the quarter was $109.13m. During the quarter, Phase I clinical trial of CHECKvacc for triple negative breast cancer will proceed to the second dose cohort. Notice of Grants received from South Korean Intellectual Property Office and European Patent Office for patent applications protecting its HER Vaxx immunotherapy.

Consolidated Statement of Cash Flow for the Quarter ended 31 March 2022

Current Quarter $A'000- 31 March 2022 Year to Date $A'000-9 Months
Net Operating Cash Flows (10,838) (20,758)
Net Investing Cash Flows nil (5)
Total Operating and Investing Cash Flows (10,838) (20,763)
Net Financing Cash Flows 1,638 100,311
Net Increase (Decrease) in Cash Held (9,200) 79,548
Cash at Beginning of Quarter/Year to Date 118,406 29,487
Cash at End of Quarter 109,127 109,127
Please click here for full details

See more ASX300 News Announcements